文献速递淋巴瘤

替沙来塞对比常规治疗在复发或难治性滤泡性淋巴瘤患者中的疗效比较

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma.
PubMed 文献 · Blood Adv · 2022-01-01

本研究将ELARA单臂试验中替沙来塞治疗复发或难治性滤泡性淋巴瘤的结局与ReCORD-FL真实世界队列的常规治疗进行间接比较。经倾向评分加权调整后,替沙来塞的完全缓解率、总缓解率、12个月无进展/事件生存率及12个月总生存率均高于常规治疗。

要点

  • 替沙来塞完全缓解率为69.1%,常规治疗为37.3%,替沙来塞约为常规治疗的1.9倍。
  • 替沙来塞12个月无进展/事件生存概率为70.5%,常规治疗为51.9%,HR=0.60(0.34-0.86)。
  • 替沙来塞12个月总生存率为96.6%,常规治疗为71.7%,HR=0.2(0.02-0.38),死亡风险降低80%。

核心结论

  • 替沙来塞与常规治疗相比,完全缓解率约高1.9倍,12个月无进展或事件生存率约高1.4倍,死亡风险降低80%。
  • 研究结果为替沙来塞在≥2线治疗后的复发或难治性滤泡性淋巴瘤患者中的获益提供了额外证据。

研究设计与样本

  • 将ELARA试验中替沙来塞的结局与ReCORD-FL真实世界回顾性队列的常规治疗进行间接治疗比较。
  • ELARA截至2021年3月29日入组98例患者,中位随访自入组起15个月。
  • ReCORD-FL数据截止2020年12月31日,纳入187例≥2线前序治疗的患者,中位随访自三线起57个月。
  • 间接比较纳入ELARA试验97例和ReCORD-FL研究143例基线因素无缺失数据的患者,采用倾向评分模型选择或匹配评估结局的治疗线,并通过优势比加权调整基线因素。
  • ELARA试验注册号为NCT03568461。

主要发现

  • 完全缓解率(95%CI)为替沙来塞69.1%(59.8%-78.3%)vs 常规治疗37.3%(26.4%-48.3%)。
  • 总缓解率(95%CI)为替沙来塞85.6%(78.7%-92.5%)vs 常规治疗63.6%(52.5%-74.7%)。
  • 12个月无进展/事件生存的Kaplan-Meier概率(95%CI)为替沙来塞70.5%(61.4%-79.7%)vs 常规治疗51.9%(40.6%-63.3%),HR=0.60(0.34-0.86)。
  • 12个月总生存率(95%CI)为替沙来塞96.6%(92.9%-100%)vs 常规治疗71.7%(61.2%-82.2%),HR=0.2(0.02-0.38)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ELARA trial indicates tisagenlecleucel (tisa-cel) is an effective anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory follicular lymphoma (r/r FL). As ELARA is a single-arm trial, this study compares tisa-cel outcomes from the ELARA trial with usual care from a real-world cohort. ELARA enrolled 98 patients as of 29 March 2021 (median follow-up: 15 months from enrollment). Usual care data were obtained from ReCORD-FL, a global retrospective study of patients with r/r FL, who met similar eligibility criteria to ELARA. With a data cutoff date of 31 December 2020, 187 patients with ≥2 preceding treatment lines were included in the ReCORD-FL (median follow-up: 57 months from third-line) study. An indirect treatment comparison was performed for 97 patients from the ELARA trial and 143 patients from the ReCORD-FL study with no missing data on baseline factors. The line of therapy for which outcomes were assessed was selected or matched between cohorts using propensity score modeling. After baseline factor adjustment via weighting by odds, complete response rate (CRR; 95% confidence interval) was 69.1% (59.8%-78.3%) for tisa-cel vs. 37.3% (26.4%-48.3%) for usual care; overall response rate was 85.6% (78.7%-92.5%) vs. 63.6% (52.5%-74.7%). Kaplan-Meier probability of being progression/event-free at 12 months was 70.5% (61.4%-79.7%) for tisa-cel vs. 51.9% (40.6%-63.3%) for usual care, with hazard ratio (HR)=0.60 (0.34-0.86); 12-month overall survival was 96.6% (92.9%-100%) vs. 71.7% (61.2%-82.2%), with HR=0.2 (0.02-0.38). In conclusion, tisa-cel was associated with a 1.9-fold higher complete response rate and a 1.4-fold higher rate of being progression or event free at 12 months vs usual care, as well as a death risk reduction of 80%. The findings provide additional evidence on the benefit of tisa-cel in patients with r/r FL after ≥2 treatment lines. This trial was registered at www.clinicaltrials.gov as NCT03568461.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Salles G, Schuster SJ, Dreyling M, et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022. PMID: 35973192. doi:10.1182/bloodadvances.2022008150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。